---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-001673"
form_type: "8-K"
ticker: "ICCC"
cik: "0000811641"
company_name: "IMMUCELL CORP /DE/"
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T18:24:16.833827+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ImmuCell reports Q4 2022 preliminary sales down 28% YoY; full year down 3.5%

## Summary
- Q4 2022 sales $3.91M vs $5.44M in Q4 2021, a decline of 28.2%.
- FY2022 sales $18.57M vs $19.24M in FY2021, down 3.5%.
- Backlog $2.5M as of Dec 31, 2022, up from $205k at Sep 30, 2022, similar to $2.4M a year ago.
- Production equipment delays and Q3 contamination events prolonged backlog and reduced output.
- Expects to submit Re-Tain CMC Technical Section to FDA in Q1 2023 with 6-month review.

## SEC filing metadata
- accession: 0001213900-23-001673
- form_type: 8-K
- ticker: ICCC
- cik: 0000811641
- company_name: IMMUCELL CORP /DE/
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/811641/000121390023001673/0001213900-23-001673-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/811641/000121390023001673/ea171435-8k_immucell.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-001673
- JSON: https://secwatch.observer/filing/0001213900-23-001673.json
- Plain text: https://secwatch.observer/filing/0001213900-23-001673.txt

## Key facts
- Earnings Releases
  IMMUCELL CORP /DE/ reported for the year ended December 31, 2022 results: revenue $18.57 million.
  - Period: for the year ended December 31, 2022
  - Revenue: $18.57 million
  - Result: preliminary results
  source text: (% Decrease) During the Three-Month Periods Ended December 31, $ 3.91 million $ 5.44 million $ (1.53 million) (28.2 )% During the Twelve-Month Periods Ended December 31, $ 18.57 million $ 19.24 million $ (675,000 ) (3.5 )% As of December 31, 2022, there was a backlog of orders equal to approximately $2.5 million, representing an increase from
  evidence_url: https://www.sec.gov/Archives/edgar/data/811641/000121390023001673/0001213900-23-001673-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.